Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis
Public ClinicalTrials.gov record NCT00726479. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomised, Double-blind, Placebo-controlled and Parallel Group Study to Evaluate the Safety and Efficacy of Four Weeks Treatment of 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS (Inhalation Powder, Hard Capsule for HandiHaler®) in Patients With COPD Associated With Chronic Bronchitis.
Study identification
- NCT ID
- NCT00726479
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- Not listed
Conditions and interventions
Interventions
- BIBW 2948 BS Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2008
- Primary completion
- Aug 31, 2008
- Completion
- Not listed
- Last update posted
- Mar 26, 2014
Started 2008
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1219.4.01001 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1219.4.01007 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1219.4.01006 Boehringer Ingelheim Investigational Site | Fort Collins | Colorado | — | — |
| 1219.4.01002 Boehringer Ingelheim Investigational Site | Stamford | Connecticut | — | — |
| 1219.4.01008 Boehringer Ingelheim Investigational Site | Rincon | Georgia | — | — |
| 1219.4.01003 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1219.4.01004 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1219.4.01005 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00726479, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2014 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00726479 live on ClinicalTrials.gov.